Plasma lipid peroxidation in sporadic Parkinson's disease.: Role of the L-dopa

被引:55
作者
Agil, A
Durán, R
Barrero, F
Morales, B
Araúzo, M
Alba, F
Miranda, MT
Prieto, I
Ramírez, M
Vives, F
机构
[1] Fac Med Granada, Dept Physiol, Granada 18012, Spain
[2] Fac Med Granada, Inst Neurosci Granada, Granada 18012, Spain
[3] Dept Pharmacol, Granada, Spain
[4] Hosp Clin San Cecilio, Motor Dis Unit, Granada, Spain
[5] Univ Granada, Fac Med, Dept Biostat, E-18012 Granada, Spain
[6] Univ Jaen, Unit Physiol, Jaen, Spain
关键词
Parkinson's disease; oxidative stress; L-dopa; catecholamines; lipid peroxidation;
D O I
10.1016/j.jns.2005.08.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oxidative stress plays an important role in the pathogenesis of neurodegenerative diseases, such as Parkinson's disease (PD). There are several methods to measure oxidative stress, being lipid peroxidation (LPO) one of the most frequently used. Endogenous Plasma LPO was determined by a spectrofluorimetric method in fifty two patients with sporadic PD and in forty controls. To know the maximum capacity of lipids to peroxidate, LPO was also measured after co-incubation with Fe2+/H2O2 (exogenous LPO). All PD patients were taken L-dopa and the effect of this treatment on LPO levels was additionally studied. Urine catecholamines and their main metabolites were also analyzed, and their possible correlation to LPO statistically studied. Endogenous plasma LPO levels were 33% higher in PD group than in control group (P < 0.001). Exogenous plasma or oxidizability was also higher in PD patients compared to controls (20%, P < 0.05). The intake of L-dopa was negatively dose-related to endogenous and exogenous plasma LPO. In conclusion, plasma of PD patients has elevated levels of LPO and also is more prone to peroxidation than that in the control group. The results also suggest an antioxidant effect of L-dopa. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 33 条
[1]   Isolation of an anti-hepatotoxic principle from the juice of Ecballium elaterium [J].
Agil, A ;
Miró, M ;
Jimenez, J ;
Aneiros, J ;
Caracuel, MD ;
García-Granados, A ;
Navarro, MC .
PLANTA MEDICA, 1999, 65 (07) :673-675
[2]  
AGIL A, 1995, CLIN CHEM, V41, P220
[3]   Hydroxy-urea protects erythrocytes against oxidative damage [J].
Agil, A ;
Sadrzadeh, SMH .
REDOX REPORT, 2000, 5 (01) :29-34
[4]   NO EVIDENCE FOR SYSTEMIC OXIDANT STRESS IN PARKINSONS OR ALZHEIMERS-DISEASE [J].
AHLSKOG, JE ;
UITTI, RJ ;
LOW, PA ;
TYCE, GM ;
NICKANDER, KK ;
PETERSEN, RC ;
KOKMEN, E .
MOVEMENT DISORDERS, 1995, 10 (05) :566-573
[5]   Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication [J].
Buhmann, C ;
Arlt, S ;
Kontush, A ;
Möller-Bertram, T ;
Sperber, S ;
Oechsner, M ;
Stuerenburg, HJ ;
Beisiegel, U .
NEUROBIOLOGY OF DISEASE, 2004, 15 (01) :160-170
[6]  
COHEN G, 1987, P UPJ S FED AM SOC E, P130
[7]  
Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556
[8]   ANTIOXIDANT DEFENSES AND LIPID-PEROXIDATION IN HUMAN-BLOOD PLASMA [J].
FREI, B ;
STOCKER, R ;
AMES, BN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (24) :9748-9752
[9]   Diagnostic criteria for Parkinson disease [J].
Gelb, DJ ;
Oliver, E ;
Gilman, S .
ARCHIVES OF NEUROLOGY, 1999, 56 (01) :33-39
[10]   PLASMA OXIDIZABILITY IN SUBJECTS WITH NORMAL GLUCOSE-TOLERANCE, IMPAIRED GLUCOSE-TOLERANCE, AND NIDDM [J].
HAFFNER, SM ;
AGIL, A ;
MYKKANEN, L ;
STERN, MP ;
JIALAL, I .
DIABETES CARE, 1995, 18 (05) :646-653